Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0000902664-25-003924
Filing Date
2025-09-02
Accepted
2025-09-02 08:15:16
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 10485
  Complete submission text file 0000902664-25-003924.txt   12474
Mailing Address 2 CORPORATE DRIVE, FIRST FLOOR SOUTH SAN FRANCISCO CA 94080
Business Address 2 CORPORATE DRIVE, FIRST FLOOR SOUTH SAN FRANCISCO CA 94080 (650) 239-2030
Senti Biosciences, Inc. (Subject) CIK: 0001854270 (see all company filings)

EIN.: 862437900 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-92581 | Film No.: 251283050
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address SUITE 2810-12, 28/F, ONE PACIFIC PLACE 88 QUEENSWAY ADMIRALTY K3 00000
Business Address SUITE 2810-12, 28/F, ONE PACIFIC PLACE 88 QUEENSWAY ADMIRALTY K3 00000 852-3851-8700
Celadon Partners SPV 24 (Filed by) CIK: 0002060465 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: SCHEDULE 13D/A